Ku­ra shares soar on pos­i­tive PhII can­cer da­ta; M&A buzz re­volves back to As­traZeneca

⇨ In­vestors are in an en­thu­si­as­tic mood when it comes to any­thing that looks pos­i­tive on the can­cer drug de­vel­op­ment side of things. To­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.